Researchers at the University of Rochester Medical Center have developed a new imaging technique that could revolutionize how eye health and disease are assessed. The group is first to be able to make out individual cells at the back of the eye that are implicated in vision loss in diseases like glaucoma. They hope their new technique could prevent vision loss via earlier diagnosis and treatment for these diseases.
In a study highlighted in the Proceedings of the National Academy of Sciences, Ethan A. Rossi, Ph.D., assistant professor of Ophthalmology at the University of Pittsburgh School of Medicine, describes a new method to non-invasively image the human retina, a layer of cells at the back of the eye that are essential for vision. The group, led by David Williams, Ph.D., Dean for Research in Arts, Sciences, and Engineering and the William G. Allyn Chair for Medical Optics at the University of Rochester, was able to distinguish individual retinal ganglion cells (RGCs), which bear most of the responsibility of relaying visual information to the brain.
There has been a longstanding interest in imaging RGCs because their death causes vision loss in glaucoma, the second leading cause of acquired blindness worldwide. Despite great efforts, no one has successfully captured images of individual human RGCs, in part because they are nearly perfectly transparent.
This new approach might eventually allow us to detect the loss of single ganglion cells. The sooner we can catch the loss, the better our chances of halting disease and preventing vision loss.
Instead of imaging RGCs directly, glaucoma is currently diagnosed by assessing the thickness of the nerve fibers projecting from the RGCs to the brain. However, by the time a change is typically detected in the retinal nerve fiber thickness, a patient may have lost tens of thousands of RGCs or more.
“In principle, this new approach might eventually allow us to detect the loss of single ganglion cells,” said Williams. “The sooner we can catch the loss, the better our chances of halting disease and preventing vision loss.”
Rossi and his colleagues were able to see RGCs by modifying an existing technology – confocal adaptive optics scanning light ophthalmoscopy (AOSLO). They collected multiple images, varying the size and location of the detector they used to gather light scattered out of the retina for each image, and then combined those images. The technique, called multi-offset detection, was performed at the University of Rochester Medical Center in animals as well as volunteers with normal vision and patients with age-related macular degeneration.
While RGCs were the main focus of Rossi’s investigations, they are just one type of cell that can be imaged using this new technique. In age-related macular degeneration, cone photoreceptors that detect color and are important for central vision are the first to die. AOSLO has been used to image cones before, but these cells were difficult to see in areas near Drusen, fatty deposits that are the most common early sign of the disease. Using their multi-offset technique in age-related macular degeneration patients, Rossi was able to assess the health of cones near Drusen and in areas where the retina had been damaged.
“This technique offers the opportunity to evaluate many retinal features that have previously remained inaccessible to imaging in the living eye,” said Rossi. “Not only RGCs, but potentially other nearly transparent cell classes as well.”
Rossi and his colleagues warn that their study included a small number of volunteers and an even smaller number of age-related macular degeneration patients. More studies will be needed to improve the robustness of the technique before it can be widely used in the clinic. Rossi is now setting up his own laboratory at the University of Pittsburgh and plans to continue working with Williams’ group in studying this technique and its ability to detect changes in retinal cells over the course of retinal diseases.
Impaired vision can be restored, a new study claimed. The findings were generated from a study of blind mice, but it is hoped that these can eventually be applied on humans as well.
According to the Scientific American, researchers at the Stanford University found that mammalian brain cells can be restored. Brain cells linked to vision can still be regrown and made functional again.This goes against traditional notion that this is not possible to do.
The work was done on visually impaired mice and with such promising results, it is hoped that humans one day will also benefit from this revelation. The researchers suggest that impairments such as glaucoma, Alzheimer’s disease, as well as spinal cord injuries can be “repaired.”
The researchers are also very optimistic, saying that even though only 5% of the damaged retinal ganglion cells of the visually impaired mice grew back, this was enough to create a difference in how the mice see things. “The brain is very good at coping with deprived inputs,” says Andrew Huberman, the Stanford neurobiologist who led the work. “The study also supports the idea that we may not need to regenerate every neuron in a system to get meaningful recovery.”